Biologics Safety Testing Market Revenue, Growth Trends, and Forecast 2032

The global Biologics Safety Testing Market in 2026 is witnessing steady expansion as pharmaceutical and biotechnology companies increasingly focus on developing advanced biologics such as monoclonal antibodies, vaccines, and cell & gene therapies. Safety testing plays a critical role in ensuring that biologic drugs meet strict regulatory requirements and are free from microbial contamination, impurities, and other harmful substances before reaching patients.

According to Fortune Business Insights, the global biologics safety testing market size was valued at USD 5.90 billion in 2024. The market is projected to grow from USD 6.40 billion in 2025 to USD 11.50 billion by 2032, exhibiting a CAGR of 8.73% during the forecast period. North America dominated the global biologics safety testing market with a market share of 37.97% in 2024. The rising demand for biologics and biosimilars worldwide is one of the key factors driving the adoption of advanced biologics safety testing technologies.

Biologics safety testing is essential throughout the drug development and manufacturing lifecycle. These tests help detect viral contamination, endotoxins, mycoplasma, residual host cell proteins, and other impurities that may compromise product quality. With the increasing complexity of modern biologics, regulatory authorities require rigorous testing procedures to ensure product safety, efficacy, and consistency.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝗿𝗶𝘃𝗲𝗿𝘀 & 𝗥𝗲𝘀𝘁𝗿𝗮𝗶𝗻𝘁𝘀:

One of the primary drivers fueling the growth of the biologics safety testing market is the exponential increase in biologics production, particularly cell and gene therapies. These innovative therapies require extensive safety assessments due to the high risk of contamination during manufacturing. As a result, pharmaceutical companies are investing heavily in advanced safety testing solutions to ensure compliance with regulatory standards.

Another major growth driver is the increasing number of clinical trials for biologic drugs. As pharmaceutical companies accelerate the development of innovative therapies, the need for reliable safety testing services is expanding rapidly. Technological advancements in testing platforms, including next-generation sequencing and automated microbiology systems, are also contributing to market growth.

However, the market also faces certain restraints. Biologics safety testing often requires specialized laboratories, high-end infrastructure, and trained professionals. The establishment and maintenance of such facilities involve significant capital investment. Additionally, stringent regulatory requirements and complex validation procedures can increase operational costs and extend testing timelines, potentially limiting market growth.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲:

The biologics safety testing market is characterized by the presence of several established global companies that provide testing instruments, kits, reagents, and contract testing services. These companies focus on expanding their service portfolios, strengthening laboratory infrastructure, and investing in advanced analytical technologies to maintain their competitive edge.

Strategic collaborations, mergers, and acquisitions are common in this market as companies aim to expand their global footprint and enhance testing capabilities. Many industry leaders are also investing in facility expansions and automation technologies to support the growing demand for biosafety testing services.

𝗧𝗼𝗽 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗜𝗻 𝗧𝗵𝗲 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗦𝗮𝗳𝗲𝘁𝘆 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁

• Merck KGaA (Germany)

• SGS Société Générale de Surveillance SA (Switzerland)

• Thermo Fisher Scientific Inc. (U.S.)

• BD (U.S.)

• Sartorius AG (Germany)

• Charles River Laboratories (U.S.)

• Eurofins Scientific (Luxembourg)

• Lonza (Switzerland)

• Waters Corporation (U.S.)

• Reading Scientific Services Ltd (U.S.)

• Abzena (U.S.)

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝘀:

The biologics safety testing market is segmented based on products & services, test type, application, and end user. In terms of products and services, the market includes kits & reagents, instruments, and services. Among these, the services segment is expected to hold a dominant share due to the growing trend of outsourcing complex safety testing procedures to specialized laboratories.

By test type, the market includes sterility testing, endotoxin/pyrogen testing, mycoplasma testing, bioburden testing, viral safety or adventitious agent testing, residual host cell protein and DNA testing, and cell line characterization. Viral safety testing is one of the most critical components in biologics manufacturing as regulatory authorities require strict validation to ensure product safety.

Based on application, the market includes monoclonal antibodies and recombinant proteins, vaccines, cell & gene therapies, blood and plasma products, and tissue or stem cell products. Monoclonal antibodies and recombinant proteins represent a significant share of the market due to their widespread use in the treatment of various diseases.

In terms of end users, the market serves pharmaceutical and biotechnology companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), academic research institutes, and government laboratories. Pharmaceutical and biotechnology companies remain the largest end users as they conduct extensive quality testing throughout the biologics development lifecycle.

Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/biologics-safety-testing-market-114846 

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀:

North America currently leads the biologics safety testing market due to the presence of a well-established biopharmaceutical industry, strong regulatory frameworks, and significant investment in research and development. The region is also home to numerous biotechnology companies and contract research organizations that require advanced biosafety testing services.

Europe represents another important market for biologics safety testing, supported by growing adoption of advanced therapies and expanding biosafety infrastructure. Meanwhile, the Asia Pacific region is emerging as a key growth hub due to increasing pharmaceutical manufacturing activities, rising healthcare investments, and the expansion of contract testing facilities in countries such as China and India.

𝗙𝘂𝘁𝘂𝗿𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗰𝗼𝗽𝗲:

The future of the biologics safety testing market looks promising as the global biologics pipeline continues to expand. Emerging technologies such as rapid microbiological methods, automated testing systems, and advanced molecular detection techniques are expected to transform biosafety testing workflows.

In addition, the shift toward animal-free testing methods and recombinant assays is gaining momentum as pharmaceutical companies seek more ethical and efficient testing alternatives. Increasing collaboration between biotechnology firms, research organizations, and regulatory bodies is also expected to accelerate innovation in safety testing technologies.

Contact us:

Fortune Business Insights™ Pvt.Phone: USA: +1 833 909 2966 (Toll-Free),United Kingdom: +44 808 502 0280 (Toll-Free),APAC: +91 744 740 1245Email: sales@fortunebusinessinsights.com